Stopping & switching

Switching From Ozempic to Mounjaro: What to Know

Ozempic and Mounjaro are diabetes drugs, so a switch involves blood sugar as well as weight. Here is what the labels say, what the switching studies found, and what changes about monitoring in the first three months.

Last verified September 14, 2026·13 sources cited·Ozempic Mounjaro

Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.

A quick orientation, because the brand names in this class trip people up constantly:

Ozempic is semaglutide, approved for type 2 diabetes, cardiovascular risk reduction in type 2 diabetes with established cardiovascular disease, and kidney outcomes in type 2 diabetes with chronic kidney disease [1].
Mounjaro is tirzepatide, approved for type 2 diabetes and, since its August 28, 2026 label expansion, for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk [5].
Wegovy is the same molecule as Ozempic at weight-management doses. Zepbound is the same molecule as Mounjaro at weight-management doses.

That matters here because an Ozempic-to-Mounjaro switch is a diabetes switch. Weight is usually part of the reason, but blood sugar is the thing being managed, and that changes what gets monitored and what other medications may need adjusting.

Where this article describes dosing, missed doses or drug interactions, it is summarizing the FDA-approved prescribing information and Instructions for Use for each product. Nothing here is medical advice, and nothing here tells you what dose to take. Dose selection, switch timing and any changes to your other diabetes medicines belong with your prescriber - follow the prescription you are given.

Why do people switch?

Switching is common. In an analysis of 42,423 patients in Poland’s largest private healthcare network with more than one GLP-1 prescription between 2018 and 2025, 29.7% switched agents at least once and 14.3% switched twice or more, with a clear acceleration in tirzepatide uptake after it entered the market [2].

The usual reasons, drawn from published switching studies and clinical protocols:

A1c above goal despite a therapeutic GLP-1 dose.
A1c at goal but more weight loss is wanted, or a need to reduce insulin requirements or daily injection burden.
Tolerability - though notably, one published hospital protocol excluded people who had severe gastrointestinal reactions leading to hospitalization or who could not tolerate a maximally dosed GLP-1 from switching between the classes at all [3].
Availability and formulary access, which drove a great deal of switching during the 2022-2025 shortages [2][4].

What dose of Mounjaro comes after Ozempic?

The Mounjaro prescribing information, revised August 2026, gives one starting dosage and no exception for prior GLP-1 exposure: the recommended starting dosage is 2.5 mg injected subcutaneously once weekly, and “if additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose,” to a maximum of 15 mg once weekly in adults [5].

Two details are worth reading carefully, because consumer coverage regularly gets them wrong by borrowing language from the Zepbound label instead.

First, the Mounjaro label does not say everyone moves to 5 mg after four weeks. It conditions each increase on whether more glycemic control is needed, which means 2.5 mg can be a destination for someone whose A1c is already at goal. Second, the Mounjaro label contains no “maintenance dosage” concept at all. The sentence “the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage” belongs to Zepbound, the weight-management label for the same molecule [14] - it is not a statement about Mounjaro, and the two labels are not interchangeable even though the drug is.

That starting dose was designed for people who had never taken a GLP-1. Whether it is the right starting point for someone coming off semaglutide 2 mg is exactly the gap clinicians have to fill themselves.

What published guidance says. A 2024 practical guide in the World Journal of Diabetes, written by a multi-country clinician group, notes there is “a lack of consensus on how to switch between different GLP-1 and dual GLP-1/GIP RA agonists, and no evidence or guidelines to follow.” Their approach: address the reason for switching first, then individualize based on the previous agent’s dose and duration and the patient’s gastrointestinal experience. For patients who could not tolerate the old drug, they suggest waiting for symptoms to settle, then starting the new agent at the lowest dose with slower up-titration. For patients switching for other reasons and tolerating treatment well, they consider starting at an equivalent dose reasonable. And specifically: “when switching from 1 mg semaglutide to tirzepatide, it is better to start tirzepatide with the 5 mg dose, as the HbA1c lowering effects of 5 mg tirzepatide and 1 mg semaglutide are similar,” escalating to 7.5 mg and 10 mg after four weeks [6]. They also advise beginning the new drug seven days after stopping a weekly agent.

What conversion tables say about themselves. The Beth Israel Lahey Health GLP-1 RA Conversion Guide, adapted from Whitley et al. in Clinical Diabetes, lines up tirzepatide 2.5/5/7.5/10/12.5/15 mg against semaglutide 0.25/0.5/1/2 mg weekly. Its own caveats are the important part: the chart is “based on the relative effect on A1c and does not address the potential for side effects,” it “does not replace clinical judgment,” patients with a history of gastrointestinal side effects should be stepped down a dose when converting, and “due to the risk for side effects, do not switch from a submaximal dose of one agent to the maximum dose of another” [7].

A hospital protocol in practice. A published case series from a clinic protocol illustrates how this plays out. Patients on semaglutide 1 mg weekly were switched to tirzepatide 7.5 mg rather than an “equivalent” 10 mg, specifically to minimize adverse reactions. Patients on oral semaglutide or lower subcutaneous doses were not considered for switching at all, because the A1c reduction from even the lowest tirzepatide treatment dose (5 mg) is substantially greater [3].

So the range of reasonable clinical practice runs from the label’s 2.5 mg to a conservative 5 or 7.5 mg for someone on a high semaglutide dose. None of those is “the” answer, and none is an instruction you should apply yourself.

Is there any equivalence research?

Yes, and it is worth understanding for what it is. A 2026 model-based analysis in Diabetes Therapy pooled arm-level data from 48 treatment arms across the SUSTAIN, STEP, SURPASS and SURMOUNT-2 programs (16,524 participants) and estimated probabilities of clinical equivalence within ±2 percentage points of weight change. It found high probabilities of equivalence for semaglutide 2.4 mg versus tirzepatide 10 mg (99.4%) and semaglutide 7.2 mg versus tirzepatide 15 mg (94.8%), with lower semaglutide doses not equivalent to higher tirzepatide doses [8].

Two limits matter. The analysis was restricted to trials in people with type 2 diabetes - trials enrolling only people without diabetes were excluded - so it speaks to this article’s population but not directly to weight-management use. And it is a model built from trial averages, not a switching rule: it tells you roughly where the two drugs land relative to each other on weight after full titration, not where anyone should start. The paper does not claim otherwise.

What happens to blood sugar during the switch?

Two things can happen, and they pull in opposite directions.

The expected improvement. The only prospective study of a direct switch enrolled people with type 2 diabetes on a stable GLP-1 dose - semaglutide 0.5, 1 or 2 mg, dulaglutide 0.75 to 4.5 mg, or liraglutide 1.2 to 1.8 mg - for at least three months, and moved them straight to tirzepatide 5 mg, skipping the 2.5 mg step. At 12 weeks, mean HbA1c fell 0.43%, fasting serum glucose fell 7.83 mg/dL and weight fell 2.15 kg, with improvements visible in continuous glucose monitoring profiles as early as week 4. Gastrointestinal events occurred in 13.2%, and 2% stopped for adverse events. No severe hypoglycemia, no deaths [9].

The transient wobble. The same paper notes that short-term variation in blood glucose during switching has been demonstrated and modeled: the DURATION-1 trial suggested fasting serum glucose rises transiently when switching from short-acting to long-acting GLP-1s, and exposure-response modeling has suggested variation when switching between weekly agents. Those changes may be temporary, but people who track their glucose closely will see them [9].

And the gap risk. If a switch turns into an interruption - a prior authorization delay, a supply problem - the consequences are measurable. When a shortage forced 69 people with type 2 diabetes off dulaglutide, mean HbA1c rose from 7.0% to 8.1% and fasting glucose from 129 to 156 mg/dL within three months, and switching to a DPP-4 inhibitor or an SGLT2 inhibitor did not make up the difference [10]. Line up the new prescription before the old one runs out.

What about my other diabetes medications?

This is the part of an Ozempic-to-Mounjaro switch that has no equivalent in a Wegovy-to-Zepbound switch.

Both labels carry a warning about hypoglycemia with concomitant use of insulin or an insulin secretagogue such as a sulfonylurea, and both state that the risk may be lowered by a reduction in the dose of the sulfonylurea (or other insulin secretagogue) or insulin [1][5]. In the published case series, every hypoglycemic event occurred in a single patient who had self-titrated their own basal insulin dose; hypoglycemia did not recur once they followed the prescribed insulin dose [3].

Both drugs also delay gastric emptying, which can affect the absorption of oral medications. The labels advise caution with oral medicines that depend on threshold concentrations or have a narrow therapeutic index, such as warfarin [5].

None of these adjustments is something to make on your own. They are the reason a switch involves an appointment rather than a pharmacy swap.

Does switching do anything beyond A1c and weight?

Some interesting signals, mostly from Japanese cohorts, and mostly about the liver.

A multicenter retrospective study (the Hokkaido-TZP study) followed 182 patients with type 2 diabetes at high risk of metabolic dysfunction-associated steatotic liver disease who switched from a GLP-1 to tirzepatide. Over six months, HbA1c, body weight and liver enzymes all fell significantly. The Hepatic Steatosis Index declined in both risk groups, and the Fibrosis-4 index fell significantly only in the high-fibrosis-risk group. Notably, the hepatic improvements were not correlated with changes in BMI or HbA1c [11].

A separate single-center retrospective study of 65 Japanese patients found that FIB-4 fell significantly in those who were GLP-1-naive when starting tirzepatide but not in those who switched from a GLP-1, with GLP-1-naive status an independent predictor of FIB-4 reduction [12]. The two results are not contradictory - they measure different populations and comparators - but they do illustrate how thin and how early this evidence is. Both are retrospective and hypothesis-generating.

A third small retrospective study looked specifically at people who switched from semaglutide 1.0 mg because of inadequate weight loss, all starting tirzepatide at 2.5 mg and escalating to either 7.5 mg (n=10) or 10 mg (n=5). Over three months the 10 mg group had a significant HbA1c reduction of 0.7% and a non-significant trend toward weight loss of 6.6 kg; the 7.5 mg group had no significant change in either. The authors suggest early escalation to 10 mg may benefit patients who responded inadequately to semaglutide [13]. Fifteen patients is very small, and the between-group differences were not statistically significant.

What do the labels say about missed doses and changing injection days?

This section summarizes what the FDA-approved prescribing information and Instructions for Use state. It is not a set of instructions for any individual reader - follow the prescription you were given and the directions from your own prescriber and pharmacist. The two products describe different rules, and it is easy to mix them up.

Ozempic (semaglutide). The label states that if a dose is missed, it should be administered as soon as possible within five days after the missed dose; if more than five days have passed, the missed dose is skipped and the next dose is given on the regularly scheduled day, after which the regular once-weekly schedule resumes. It also states that the day of weekly administration can be changed if necessary as long as the time between two doses is at least two days (more than 48 hours) [1].

Mounjaro (tirzepatide). The label states that if a dose is missed, it should be administered as soon as possible within four days (96 hours) after the missed dose; if more than four days have passed, the missed dose is skipped and the next dose is given on the regularly scheduled day. The day of weekly administration can be changed if necessary as long as the time between the two doses is at least three days (72 hours) [5].

On overlap, the two labels are quieter than you might expect. The Wegovy and Zepbound labels - the weight-management products - carry an explicit Limitations of Use statement that concomitant use with other products containing the same molecule, or with any other GLP-1 receptor agonist, is not recommended [14][15]. The Ozempic and Mounjaro labels do not carry that statement. The published switching guidance fills the gap instead: the World Journal of Diabetes practical guide advises beginning the new drug seven days after a weekly agent is stopped, and the health-system conversion guidance treats these as sequential rather than overlapping therapies [6][7]. Timing is a prescriber’s decision, and it is a fair thing to ask about.

How should I prepare for the appointment?

Bring the information a prescriber needs to pick a starting dose:

Your current Ozempic dose and how long you have been on it.
How you tolerated each step up, especially any nausea, vomiting or diarrhea and how long it lasted.
Your most recent A1c and your glucose logs or CGM data if you use them.
Everything else you take for diabetes, especially insulin or a sulfonylurea.
The date of your last injection.
Why you want to switch - A1c, weight, injection burden, side effects, cost, coverage.
Insurance details: whether Mounjaro is on formulary, what tier, and any prior authorization requirements. Coverage rules for a diabetes product often differ from those for a weight-management product even when the molecule is identical.

Questions worth asking: Is this starting dose based on the label or on your judgment for me? Should my insulin or sulfonylurea dose change? How should I monitor my glucose over the first month? When do we recheck A1c? What do I do if the pharmacy or the plan delays things and I run out?

What is the bottom line?

Ozempic to Mounjaro is a well-trodden switch, but it is a restart on a different molecule, not a dose swap. The label starts everyone at 2.5 mg. Published clinical guidance and health-system protocols sometimes start higher for people who tolerated a therapeutic semaglutide dose, using tables built on A1c effect that come with explicit warnings against aggressive jumps. Head-to-head, tirzepatide outperformed semaglutide 1 mg on both A1c and weight in SURPASS-2, which is why the switch is popular. The practical work is in the details around it: not overlapping the two drugs, adjusting insulin or sulfonylurea doses if needed, watching glucose closely for the first month, and making sure a coverage delay does not turn a switch into a gap.

Sources

Questions people ask

What Mounjaro dose comes after Ozempic?

The Mounjaro label, revised August 2026, sets one starting dosage for everyone - 2.5 mg once weekly - and says the dosage is increased in 2.5 mg increments after at least four weeks on the current dose if additional glycemic control is needed. It makes no exception for previous GLP-1 exposure and, unlike the Zepbound label, does not describe any dosage as a 'maintenance' dosage. Some clinicians start people who tolerated a high Ozempic dose at 5 mg instead, based on published switching data, but that is a clinical decision rather than a labeled instruction.

Is there an official conversion between Ozempic and Mounjaro doses?

No. Published conversion tables such as the Beth Israel Lahey Health guide line up tirzepatide and semaglutide doses by their relative effect on A1c, not on weight, and state that they do not replace clinical judgment and do not address side effects.

What happens to my blood sugar during the switch?

It can move in both directions temporarily. A prospective study of people switching directly to tirzepatide 5 mg found HbA1c fell 0.43% and fasting glucose fell 7.83 mg/dL by 12 weeks. Earlier research has shown transient glucose variation when switching between agents with different durations of action, which is why monitoring matters.

Do I need to change my other diabetes medications?

Possibly. Both labels warn that combining with insulin or a sulfonylurea raises hypoglycemia risk and suggest considering a lower dose of those medicines. That adjustment is a prescriber's call, not something to do independently.

How long should I wait between the last Ozempic dose and the first Mounjaro dose?

No label sets a washout period. The Ozempic and Mounjaro labels do not carry the Limitations of Use statement about concomitant GLP-1 use that appears in the Wegovy and Zepbound labels, so the guidance here comes from the literature rather than the label: one practical guide published in 2024 suggests starting the new drug seven days after a weekly agent is stopped. Your prescriber sets the timing.

Is Mounjaro better than Ozempic for blood sugar?

In the SURPASS-2 head-to-head trial, all tirzepatide doses were superior to semaglutide 1 mg for both A1c and weight reduction. Mounjaro was also approved in August 2026 to reduce cardiovascular risk in type 2 diabetes, following SURPASS-CVOT.

Will I lose more weight after switching?

Often, though the amount varies. In one small Japanese retrospective study of people who switched from semaglutide 1.0 mg because of inadequate weight loss, escalating to tirzepatide 10 mg produced a significant HbA1c reduction and a non-significant trend toward weight loss over three months, while 7.5 mg produced neither.

Will insurance cover the switch?

It depends entirely on the plan and the indication. Coverage rules for diabetes products differ from weight-management products, and formularies change on quarterly cycles. Check before the last pen runs out.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.